1
Indications / Contraindications
Indications
- T1a RCC (≤4 cm) — excellent candidate; local tumor control comparable to partial nephrectomy; preferred in poor surgical candidates
- T1b RCC (4–7 cm) — acceptable for high surgical risk patients; higher recurrence rate than T1a; multi-antenna technique required
- Significant comorbidities / poor surgical risk — cardiac, pulmonary, or renal disease making surgery prohibitive
- Solitary kidney — nephron-sparing is critical; ablation avoids open or laparoscopic nephrectomy
- Bilateral RCC — staged bilateral ablations; preserve maximum renal parenchyma
- Von Hippel-Lindau disease / hereditary RCC syndromes — multiple tumors over lifetime; ablation allows repeat treatments while preserving function
- Local recurrence after prior partial nephrectomy
- Exophytic clear cell RCC — best results; posterior exophytic ideal for prone CT approach
Contraindications
- Active infection at access site
- Uncorrectable coagulopathy (INR >1.5, platelets <50K)
- Central tumor with direct collecting system involvement (thermal injury → urine leak, fistula, obstruction)
- Tumor adjacent to ureter (<1 cm) without hydrodissection capability
- Solitary kidney with central large tumor — partial nephrectomy may be safer option
- Metastatic RCC — ablation is not curative; may treat dominant symptomatic lesion as palliation
Ablation Modalities
- Microwave (MWA) — preferred: Faster, larger zones, no heat sink effect from vessels. 915–2450 MHz, 65–100 W, 5–10 min per position.
- Radiofrequency (RFA) — alternative: Heat sink effect limits use near vessels; conductive urine affects current; multiple electrodes needed for larger tumors.
- Cryoablation: Ice ball visible on CT (precise margin visualization); excellent for central tumors; two-cycle freeze-thaw-freeze; longer procedure time.
Expected Local Tumor Control Rates
- T1a (≤4 cm): 90–95% local tumor control; comparable to partial nephrectomy in most series
- T1b (4–7 cm): 80–85%; higher local recurrence; surgery preferred if patient is fit
- Factors reducing success: Size >3 cm, endophytic location, proximity to collecting system/ureter, prior renal surgery
2
Pre-Procedure Checklist
Biopsy confirmation. Consider biopsy at time of ablation (or prior) to confirm RCC. 20–30% of small renal masses are benign on biopsy (oncocytoma, angiomyolipoma). If benign, ablation may be deferred. Many operators biopsy at same session as planned ablation and proceed regardless to spare a visit.
CT planning (dedicated thin-slice). Contrast-enhanced CT for ablation planning. Assess: tumor size, location (exophytic vs endophytic vs central), distance to collecting system and ureter, relationship to adjacent organs (bowel, liver, spleen), access route planning, patient positioning (prone vs lateral).
Labs. CBC, coagulation panel (INR <1.5, platelets >50K per SIR Cat 2–3), BMP (creatinine/GFR — nephron-sparing critical; establish baseline).
Anticoagulation hold. Per SIR Category 2–3: hold oral anticoagulants. Heparin: 4–6 h; LMWH: 24 h; Warfarin: 5 days (bridge if needed); DOACs: 24–48 h. Antiplatelets as appropriate for risk.
Urology coordination. Discuss case before proceeding. If complete ablation fails, surgical salvage must be possible. For tumors within 1 cm of collecting system: coordinate with urology for retrograde cold saline ureteral irrigation during ablation.
Hydrodissection supplies. D5W (dextrose 5% in water) NOT normal saline. D5W is non-ionic — does not conduct heat — creates an insulating fluid layer between tumor and adjacent critical structures. Stock 500 mL–1 L bags. Essential for tumors near bowel, ureter, or collecting system.
Patient positioning plan. Posterior/posterolateral tumors — prone or prone oblique (most common). Lateral decubitus or supine for anterior tumors (less common). Confirm positioning can achieve access trajectory on planning CT.
General/deep sedation / MAC coordination. Mandatory for MWA. Breath-hold coordination is essential for CT-guided antenna placement. Anesthesia must be able to suspend respirations on command for CT guidance sweeps.
3
Relevant Anatomy
Kidney and Collecting System
- Position: Retroperitoneal, surrounded by Gerota's fascia. Right kidney lower than left (liver displaces cephalad). Both slightly oblique on axial CT.
- Collecting system: Renal pelvis centrally, infundibula to calyces. Thermal ablation within 1 cm of collecting system → risk of urine leak, infundibular stricture, ureteropelvic junction damage.
- Ureter: Exits UPJ and courses inferiorly along psoas. Upper ureter within 1 cm of lower pole medial tumors → thermal injury → ureteral stricture. Hydrodissection with D5W displaces ureter away from ablation zone.
- Renal hilum: Renal artery, vein, and pelvis. Central tumors near hilum: highest risk; surgery preferred if technically feasible.
Tumor Location Classification
- Exophytic (protrudes beyond renal contour) — easiest to ablate; lowest complication risk; best outcomes; ideal for prone CT access
- Mixed — partially exophytic/partially intrarenal; intermediate risk
- Endophytic (entirely within parenchyma) — harder to ablate with adequate margin; more parenchymal loss; higher recurrence risk
- Central (near collecting system/hilum) — highest risk; proximity to ureter and vessels; ureteral irrigation mandatory; cryoablation preferred by many operators for better ice ball visualization
Adjacent Organ Risk (Prone Access)
- Ribs / intercostal neurovascular bundle (upper pole tumors → intercostal approach may be needed)
- Lung / pleura (upper pole → pneumothorax risk)
- Liver (right side lateral access)
- Spleen (left side lateral access)
- Descending colon (posterior left kidney)
- Bowel loops (especially anterior tumors)
4
Technique
CT-guided microwave ablation + community cards
Supplies
CT scanner (CT fluoroscopy or intermittent CT)
Microwave ablation system (Emprint or equivalent)
Microwave antenna 13G or 17G
18G core biopsy gun (if biopsy at same session)
D5W (500 mL–1 L for hydrodissection)
18–22G spinal needle (hydrodissection)
1% lidocaine
Skin marker
Sterile drape
Foley catheter (optional — cold saline irrigation for central tumors)
Steps
1
Planning CT + skin marking
Mark skin entry site using grid or free-hand marking under CT. Plan access to avoid ribs, bowel, and adjacent organs. Approach from posterolateral in prone position for most posterior tumors.
2
Hydrodissection (if needed)
Before antenna placement, advance 18–22G spinal needle to space between tumor and critical adjacent structure under CT guidance. Inject D5W (NOT normal saline — saline conducts heat) to create a fluid buffer. Typical volume: 50–200 mL. Can dope with 1–2% contrast. CT check to confirm adequate separation (≥1 cm). May need to re-inject during procedure as D5W absorbs. Essential for tumors near ureter, bowel, or collecting system.
3
Biopsy (if performing at same session)
Core biopsy before ablation — ablation destroys histologic architecture. Advance 18G biopsy gun into viable tumor using CT guidance. Obtain 2–3 cores from enhancing (viable) edge of tumor. Send for permanent histology. Proceed with ablation regardless if clinically indicated. I like to place probe(s) in the center of the mass then the biopsy device along the periphery to sample the margin of the lesion (if possible). This ensures you have good probe position prior to biopsy and removes the possibility of obscuring the lesion due to hemorrhage from the biopsy.
4
Antenna placement
Under CT guidance (intermittent CT with breath-hold), advance microwave antenna using coaxial technique. Target center of tumor for T1a (≤4 cm). For T1b, plan multiple overlapping antenna positions before starting. Confirm tip position with CT before activating. Communicate with anesthesia for controlled breath-holds during CT sweeps.
5
Ablation
Activate microwave system per protocol. Typical T1a: 65–100 W × 5–8 minutes (single antenna). During ablation: low-density zone expanding around antenna = ablation zone. Target: ablation zone with ≥5–10 mm margin beyond all tumor edges. CT check during ablation to monitor zone size. Stop if antenna tip becomes dislodged.
6
Mid-ablation CT assessment
Non-contrast CT after initial ablation to assess zone size relative to tumor. Is there adequate coverage of all tumor margins? Any residual hyperdense rim suggesting viable tumor beyond ablation zone? If margin is inadequate, plan repositioning before antenna withdrawal.
7
Repositioning for larger / incompletely covered tumors
For T1b or tumors with inadequate initial coverage: reposition antenna to overlapping position. Allow 1–2 mm overlap between adjacent ablation zones. Multi-antenna simultaneous ablation for tumors >4 cm. Each position confirmed on CT before activation.
8
Completion CT (with contrast)
Arterial phase CT to assess ablation coverage. Absent enhancement within ablation zone = complete ablation. Residual arterial enhancement at tumor margin = incomplete → additional ablation pass if technically feasible. Document ablation zone dimensions and relationship to tumor edges.
9
Track ablation on withdrawal
Ablate the antenna track during withdrawal to reduce tumor seeding along the needle tract and reduce bleeding from the biopsy/ablation channel. Most modern systems perform this automatically. Confirm on post-procedure CT.
10
Post-procedure CT
Non-contrast CT to assess for immediate complications: perinephric hematoma (common — small hematoma is expected), pneumothorax (upper pole access), bowel injury (if bowel was adjacent). Compare ablation zone to tumor size on final images. Document hematoma size for baseline comparison.
Sign in to view and create community cards
5
Troubleshooting
Problem
Antenna deflected during insertion (rib or fascial resistance)
Likely cause: Intercostal or paraspinal approach with rib in path; dense perirenal fascia deflecting antenna tip.
Next step: Use coaxial approach — advance outer sheath first, confirm position, then introduce antenna through sheath. Blunt inner trocar before transitioning to sharp antenna tip. If rib is obstructing, adjust angle 1–2 cm cephalad or caudad. Oblique/angled gantry CT can help with difficult trajectories.
Problem
Inadequate ablation zone (residual enhancement on completion CT - if performed)
Likely cause: Antenna not optimally centered, heat sink from adjacent vessel, insufficient power/time, large tumor requiring multiple positions.
Next step: Reposition antenna to the enhancing margin and perform additional overlapping ablation at same session. If not safely achievable same-session (bleeding, patient fatigue, bowel proximity), obtain 1-month follow-up MRI and re-ablate any LR-TR viable residual at that time. Document all decisions clearly.
Problem
Collecting system thermal injury (urine leak, flank pain post-procedure)
Likely cause: Tumor within 1 cm of collecting system without adequate thermal protection. Retrograde irrigation not performed or insufficient.
Next step: Prevention is key — for any tumor within 1 cm of collecting system, coordinate with urology before procedure for retrograde cold saline ureteral irrigation via Foley catheter during ablation. This cools the collecting system from inside while ablation proceeds. If injury occurs post-procedure: monitor for urinoma formation, nephrostomy drainage if obstruction develops, urology follow-up.
Problem
Bowel interposition along planned access trajectory
Likely cause: Descending or sigmoid colon posteriorly, small bowel for anterior tumors. Common with anteriorly located tumors or in thin patients.
Next step: D5W hydrodissection — inject via small spinal needle into the plane between bowel and kidney to displace bowel. 50–150 mL often sufficient. If bowel cannot be displaced with hydrodissection: try CT fluoroscopy for real-time guidance at a slightly different angle. Last resort: laparoscopic surgical displacement (rare). Never advance ablation antenna through bowel.
Problem
Expanding perinephric hematoma / hemodynamic instability
Likely cause: Renal parenchymal or capsular vessel injury from antenna placement. Small stable hematomas are common and expected; expanding hematoma with vital sign changes is a procedural emergency.
Next step: Small stable perinephric hematoma on completion CT — observe, document size, discharge with instructions to return for worsening pain or hemodynamic change. Expanding hematoma + hemodynamic instability → urgent CT angiography → super-selective renal artery embolization vs surgical consultation. Track access site as well for bleeding.
6
Complications
Common
- Perinephric hematoma (10–20%) — most common; usually subclinical; seen on completion CT; rarely requires intervention
- Post-ablation pain — significant first 48–72 h; oral NSAIDs + opioids PRN
- Transient hematuria — common with collecting system proximity; usually self-limited
Serious
- Incomplete ablation / local recurrence (5–15%) — size and location dependent; re-ablation or surgical salvage
- Collecting system injury / urine leak (2–5%) — urinoma, pyelonephritis, fistula; collecting system irrigation is protective
- Ureteral stricture (1–3%) — central tumors near upper ureter; delayed presentation; may require ureteral stenting
- Bowel injury — rare with proper hydrodissection; thermal perforation requires surgical consultation
- Pneumothorax — upper pole access; chest tube if >15–20% or symptomatic
- Skin/subcutaneous thermal injury — antenna track near skin in thin patients; track ablation timing
- Needle tract seeding (<1%) — track ablation is protective
7
Post-Procedure Care
Immediate Recovery
- 2–4 h observation post-procedure; most patients same-day discharge or 23 h admission
- Monitor vitals, urine output, and flank pain
- Pain management: oral NSAIDs + opioids PRN; post-ablation pain significant for 48–72 h
- Activity restrictions: no heavy lifting, strenuous exercise for 1–2 weeks
- Post-procedure CT (non-contrast): confirm ablation zone, assess hematoma size
Renal Function Monitoring
- GFR at 1 month and ongoing — critical in solitary kidney patients
- Ablation of T1a in a kidney with contralateral normal kidney: minimal functional impact expected
- Solitary kidney or bilateral ablation: closer GFR monitoring; nephrology involvement if pre-existing CKD
- Resume anticoagulation 24–48 h post-procedure (or per risk assessment)
Imaging Follow-up Schedule
- 1 month: Contrast CT or MRI — primary LR-TR assessment. Arterial phase enhancement ≥15 HU = residual viable tumor → plan re-ablation.
- 3 months: CT or MRI
- 6 months: CT or MRI
- 12 months: CT or MRI
- Then annually — ongoing surveillance per urology/oncology protocol
Residual / Recurrent Tumor
- Arterial phase enhancement on follow-up imaging = residual or recurrent viable tumor
- Threshold: ≥15 HU above pre-contrast (some centers use 20 HU)
- Non-enhancing ablation zone = treatment success
- Re-ablation: percutaneous, same technique — second ablation is standard first response
- Surgical salvage (partial nephrectomy) if re-ablation is not feasible due to location or prior ablation zone
8
Critical Pearls
❖
Margin is everything. Target ≥5–10 mm ablation margin beyond all tumor edges on every axis. This is technically the hardest part — central tumors, near collecting system, and large T1b tumors all make achieving adequate margin challenging. Local recurrence correlates directly with inadequate margin, not with ablation modality.
❖
D5W hydrodissection: NOT normal saline. Saline conducts heat and will not protect adjacent structures — it concentrates the thermal injury. D5W is non-ionic, does not conduct heat, and creates a genuine insulating fluid buffer. This is the single most powerful safety tool for protecting adjacent bowel, ureter, and collecting system.
❖
Collecting system protection: coordinate with urology before the procedure starts. For tumors within 1 cm of the collecting system, urology should place a ureteral catheter and run continuous cold saline irrigation during ablation. This cools the collecting system from inside and dramatically reduces the risk of stricture and urine leak. Do not start ablation without this in place for high-risk tumors.
❖
Cryoablation advantage: the ice ball is visible on CT. With MWA, you are estimating the ablation zone from a low-density region that may not perfectly correlate with lethal temperature margin. With cryoablation, the sharply defined ice ball on CT gives precise margin visibility. Many operators prefer cryo for central and challenging tumors where margin confidence is critical.
❖
Biopsy first: 20–30% of small renal masses are benign. Oncocytoma and angiomyolipoma do not require ablation. Biopsy at same session is efficient (saves a visit) — some operators biopsy immediately before ablation and proceed regardless for indeterminate masses. If prior biopsy was benign and low-risk appearance, spare the procedure.
❖
Post-ablation enhancement threshold: ≥15 HU above pre-contrast = viable tumor. Non-enhancing zone = success. Perilesional arterial enhancement (rim enhancement) from inflammatory reaction can mimic residual tumor in the first few weeks — this is why the 1-month scan is preferred over immediate post-procedure contrast for definitive response assessment. When in doubt, follow at 3 months before re-treating.
9
Size and Location Outcomes Reference
| Tumor Size | Modality | Expected Complete Ablation | Notes |
|---|---|---|---|
| ≤3 cm exophytic | MWA or RFA | 95–98% | Excellent candidate; single antenna; posterior exophytic ideal |
| 3–4 cm exophytic | MWA | 90–95% | Single large antenna; margin discipline critical |
| 4–5 cm (T1b) | MWA (multi-antenna) | 80–88% | Multiple overlapping positions; higher local recurrence; close follow-up |
| >5 cm | MWA | 65–75% | Surgery preferred if patient is operative candidate; ablation for inoperable only |
Location Risk Stratification
- Posterior exophytic — Low risk — ideal for prone CT approach; best outcomes
- Lateral exophytic — Low-moderate risk — lateral decubitus approach; confirm no spleen/liver in path
- Upper pole — Moderate risk — ribs and lung/pleura in trajectory; pneumothorax risk; intercostal access often needed
- Central (<1 cm collecting system) — High risk — ureteral irrigation mandatory; cryoablation preferred by many
- Hilar — Very high risk — vessels + collecting system + ureter all at risk; surgery preferred if operative candidate
Nephron-Sparing Impact
- Percutaneous ablation: minimal GFR impact for T1a in a normal contralateral kidney (<5% GFR decline expected)
- Partial nephrectomy: ~10–15% GFR decline
- Radical nephrectomy: ~30–50% GFR decline
- Solitary kidney: ablation is a major advantage over any surgery; preserves remaining parenchyma
- VHL / hereditary RCC: ablation allows repeat nephron-sparing treatment over a lifetime of new tumor development
10
References & Resources
Primary sources · Key data · Related procedures
Key Guidelines
- AUA Guidelines for Renal Mass Management 2021
- SIR Standards of Practice for Thermal Ablation
- ACR Appropriateness Criteria for RCC
Primary References
- Ljungberg B et al. (EAU Guidelines on Renal Cell Carcinoma). Eur Urol. 2019;75(5):799-810.
- Gervais DA et al. Renal cell carcinoma: clinical experience and technical success with radio-frequency ablation of 42 tumors. Radiology. 2003;226(2):417-424.
- Johnson DB et al. Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review. J Urol. 2004;172(3):874-877.
- Campbell SC et al. Renal mass and localized renal cancer: AUA Guideline. J Urol. 2021;206(Suppl 1):199-203.